By Blake Brittain WASHINGTON, May 28 (Reuters) – A U.S. appeals court on Thursday overturned a $452 million verdict that medical device maker Insulet won against Korean rival EOFlow for allegedly stealing trade secrets related to its insulin-pump technology. The Washington-based U.S. Court of Appeals for the Federal Circuit reversed the verdict after finding that […]
Health
US court overturns Insulet’s $452 million insulin-pump trade secret verdict against EOFlow
Audio By Carbonatix
By Blake Brittain
WASHINGTON, May 28 (Reuters) – A U.S. appeals court on Thursday overturned a $452 million verdict that medical device maker Insulet won against Korean rival EOFlow for allegedly stealing trade secrets related to its insulin-pump technology.
The Washington-based U.S. Court of Appeals for the Federal Circuit reversed the verdict after finding that Insulet had waited too long to bring its lawsuit.
A federal jury in Massachusetts had determined in 2024 that EOFlow owed $452 million in damages for misappropriating Insulet trade secrets to create a competitor to Insulet’s Omnipod, a wearable insulin pump for diabetes patients.
(Reporting by Blake Brittain in Washington)